Admission Date:  [**2196-12-5**]       Discharge Date:  Date of Birth:   [**2163-8-26**]       Sex:  F   HISTORY OF PRESENT ILLNESS:  The patient is a 33-year-old woman with a history end-stage renal disease secondary to lithium toxicity, status post cadaveric renal transplant in [**2196-6-17**] complicated by post-transplantation who presented with fever to 102 degrees Fahrenheit, diffuse abdominal pain times one day, recent discharge on Friday prior to admission.
Rapamycin prednisone 40 mg, tapered down to 20.
Prednisone was increased to 20 mg after she received four days of Solu-Medrol 500 mg intravenously q.d.
Nasogastric tube was placed.
She had been on hemodialysis times four years.
Status post renal transplant in [**2196-6-17**] complicated by post-transplantation lymphoproliferative disorder.
Appendectomy in [**2179**].
CMV disease diagnosed several weeks prior to PTLD, treated with prolonged course of IV ganciclovir.
MEDICATIONS ON ADMISSION:  Prednisone 20 mg p.o.
q.d., Depakote 1000 mg p.o.
q.p.m., Zoloft 75 mg p.o.
q.d., atenolol 25 mg p.o.
q.d., Norvasc 2.5 mg p.o.
q.d., Lamictal 50 mg p.o.
q.d., Seroquel 25 mg p.o.
q.d., valganciclovir 900 mg p.o.
q.d., Lipitor 20 mg p.o.
q.d., Prevacid 30 mg p.o.
q.d., Bactrim-SS 1 tablet p.o.
In general, she was a cushingoid-appearing woman, uncomfortable, but in no acute distress.
LABORATORY DATA ON PRESENTATION:  Laboratories on admission were notable for a white blood cell count of 3, hematocrit of 18.3, platelets of 80.
RADIOLOGY/IMAGING:   A CT scan revealed stable masses in the transplant and kidney, consistent with post-transplantation lymphoproliferative disorder.
RENAL:  She was initially given intravenous Solu-Medrol 500 mg followed by 250 mg intravenously for a total of three days, and the placed on prednisone 20 mg p.o.
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER:  The patient received her second and third doses of rituximab for this during this hospitalization, and she had a follow-up CT scan which revealed slight improvement.
She received valganciclovir initially, but then that was held because of possible bone marrow suppression.
PANCYTOPENIA:  This was believed to be secondary to medication use, but there was also concern about viral etiology.
Because of this her rapamycin was discontinued.
Her valganciclovir was held, and she received Neupogen for her decreased white blood cell count.
She also had neutropenic precautions, and she received 2 units of packed red blood cells on the day of admission because her hematocrit was low in setting of kidney biopsy.
NEUROLOGY/PSYCHIATRY:  She was followed by the Psychiatry liaison consultation team because of her bipolar disorder, and they continued her medication of Lamictal, Depakote, Zoloft, and Ativan p.r.n.
